Cytokinetics, Inc. — FY 2014 Form 10-K
Reporting period: Year ended December 31, 2014. The filing was signed March 6, 2015. Cytokinetics is a clinical-stage biopharmaceutical company developing muscle-function therapies; it had no products approved for sale and no commercial product revenue.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $46.9 million | $30.6 million |
| Research and development expense | $44.4 million | $49.5 million |
| General and administrative expense | $17.3 million | $15.1 million |
| Operating loss | $(14.8) million | $(33.9) million |
| Net loss | $(14.6) million | $(33.7) million |
| Net loss per share | $(0.41) | $(1.24) |
| Net cash used in operations | $44.8 million | $7.7 million |
| Cash, cash equivalents and investments at year-end | $83.2 million | $80.2 million |
| Working capital at year-end | $107.3 million | $52.6 million |
Revenue was mainly collaboration, research reimbursement, license and milestone income—not product sales. The company reported an annual operating margin of approximately negative 31% and net margin of approximately negative 31%. No debt was outstanding at year-end; equipment financing had been repaid in 2012. Total liabilities were $40.9 million, including $33.6 million of deferred revenue. Management said existing cash and investments should fund operations for at least 12 months.
Changes versus prior year and unusual items
- Revenue increased 53%, while net loss narrowed by $19.1 million. Higher collaboration and milestone revenue, including Astellas-related amounts, contributed to the improvement; results remain dependent on partner payments and revenue recognition timing.
- R&D expense fell 10%, primarily because BENEFIT-ALS clinical costs declined after the trial was completed. G&A expense rose 14%, including higher staffing and commercial-planning costs.
- Operating cash use rose to $44.8 million from $7.7 million. The filing reports a $46.6 million increase in related-party receivables, chiefly Astellas, and $17.4 million of deferred revenue in the cash-flow reconciliation. Year-end related-party receivables were $46.6 million, including $45.0 million due from Astellas.
- Financing provided $48.9 million, including $37.5 million net proceeds from a public offering and approximately $9.1 million net proceeds from the Astellas share sale. The Astellas share purchase brought in $10.0 million gross proceeds in December.
- Fourth-quarter revenue was $21.8 million and reported net income was $8.4 million, compared with a $6.0 million loss in Q3. The annual result remained a net loss; the filing’s quarterly figures reflect collaboration and license accounting rather than product sales.
Pipeline, outlook and principal risks
- Tirasemtiv (ALS): BENEFIT-ALS missed its primary ALSFRS-R endpoint (p=0.11), but showed a statistically significant reduction in decline in slow vital capacity. Serious adverse events were more frequent with tirasemtiv than placebo (9.0% versus 5.4%), and post-randomization withdrawals were higher. The company planned a Phase III program, targeting initiation in Q2 2015, subject to regulatory discussions and acceptance of respiratory-function endpoints.
- CK-2127107 (SMA and other muscle weakness indications): Five Phase I trials were completed. Cytokinetics expected to initiate a Phase II SMA trial in the second half of 2015 under its expanded Astellas collaboration.
- Omecamtiv mecarbil (heart failure): Amgen-led oral Phase II COSMIC-HF results were expected in the second half of 2015. The earlier ATOMIC-AHF trial did not meet its primary dyspnea endpoint; the filing also reported more post-randomization myocardial infarctions in treatment groups than placebo groups.
- 2015 expense outlook: R&D expense projected at $56–59 million and G&A at $18–20 million, both above 2014 levels. Management expected increased R&D spending as programs advanced.
- Astellas agreement: The December 2014 amendment expanded the collaboration to neuromuscular indications. Cytokinetics reported a $15 million Phase II milestone in 2014 and was eligible for substantial future milestones, reimbursements and royalties; these are contingent and not assured. The $30 million upfront payment was received in January 2015, not in 2014.
- Key risks: Continued operating losses and need for additional capital; uncertain clinical efficacy, safety and regulatory acceptance of trial endpoints; dependence on Amgen and Astellas’ funding and development decisions; partner and vendor execution; and patent, manufacturing, reimbursement and competitive risks. The company also disclosed litigation against its BENEFIT-ALS data-management vendor concerning randomization-system errors that delayed the trial and increased costs; the outcome and potential recovery were uncertain.
Most important facts for investors to verify
- Cash collection and timing of the $45.0 million Astellas receivable, and the composition and recognition schedule of $33.6 million in deferred revenue.
- Whether tirasemtiv’s planned Phase III trial began as expected, and whether regulators accepted SVC or other respiratory measures as endpoints supporting registration.
- Full clinical results, safety findings and timing for COSMIC-HF and the planned CK-2127107 Phase II SMA study.
- Actual 2015 spending and cash runway versus management’s 12-month liquidity assertion and expense guidance.
- Progress and financial terms of the Pharm-Olam litigation, and any further trial-data or vendor-related costs.